MedTrace Logo

Subcutaneous Semaglutide in Systemic Scleroderma

NCT06149260 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-03-05

No results posted yet for this study

Summary

This trial will study the safety and efficacy of subcutaneous semaglutide for the treatment of Systemic Sclerosis

Conditions

  • Scleroderma, Systemic
  • Fibrosis
  • Semaglutide

Interventions

DRUG

Semaglutide Pen Injector

Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and then maintained 0.5mg until the end of treatment in total 24 weeks.

Sponsors & Collaborators

  • Second Xiangya Hospital of Central South University

    lead OTHER

Principal Investigators

  • Rong Xiao, MD · Department of Dermatology, Second Xiangya Hospital of Central South University, Changsha, China

  • Licong Liu, MD · Second Xiangya Hospital

  • Yaqian Shi, MD · Second Xiangya Hospital

  • Zhuotong Zeng, MD · Second Xiangya Hospital

  • Zhan Yi, MD · Second Xiangya Hospital

  • Xiangning Qiu, MD · Second Xiangya Hospital

  • Ruixuan Zhu, MD · Second Xiangya Hospital

  • Yi Wei, MD · Second Xiangya Hospital

  • Ke Chai, MD · Second Xiangya Hospital

  • Hao Ren, MD · Second Xiangya Hospital

  • Yangfan Xiao, MD · Second Xiangya Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-29
Primary Completion
2024-08-29
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06149260 on ClinicalTrials.gov